Source Facts: Financial Supervisory Service Electronic Disclosure System (DART) / 2024-06-28
Disclosure Type: Other Market Information
💡 3-Second Summary
According to amendments in the Korean Standard Industrial Classification (KSIC) and the KRX listing enforcement rules, Celltrion’s sub-class industry classification has been updated from “Manufacture of basic pharmaceutical products and biological products” to “Manufacture of basic pharmaceutical products,” effective July 1, 2024.
📊 1. [Key Disclosure Content & Major Financial Figures Summary]
- Company Name: Celltrion, Inc.
- Industry Classification Details & Codes:
- Before Modification: Manufacturing (03) ➔ Manufacture of pharmaceuticals, medicinal chemical and botanical products (21) ➔ Manufacture of basic pharmaceutical products and biological products (01)
- After Modification: Manufacturing (03) ➔ Manufacture of pharmaceuticals, medicinal chemical and botanical products (21) ➔ Manufacture of basic pharmaceutical products (01)
- Effective Date of Modification: July 1, 2024
- Reason for Modification: Revisions to the Korean Standard Industrial Classification (KSIC) managed by Statistics Korea and the Enforcement Rules of the KOSPI Market Listing Regulation.
- Legal Ground: Article 132 of the Enforcement Rules of the KOSPI Market Listing Regulation.
- Issuing Entity: Korea Exchange (KRX)
📈 2. [Expert Perspective: What This Disclosure Means for Investors]
This filing represents an administrative announcement informing the public of an update to Celltrion’s sub-class industry designation under the standardized classification system, rather than an operational shift in the company’s core business model or production segments.
From a financial perspective, the divisions of manufacturing (03), pharmaceutical manufacturing (21), and the final digits of the classification code (03-21-01) remain identical. This alteration is driven strictly by institutional revisions in KSIC guidelines and Article 132 of the KOSPI Market Enforcement Rules. Consequently, this change does not impact any qualitative or quantitative parameters of Celltrion’s consolidated balance sheet, operational earnings, or actual cash flow. Investors should evaluate this modification solely as an administrative data update.
📝 Editor’s Comment (by K-STOCK Editor)
This regulatory update registers the administrative transition of Celltrion’s designated sub-class industrial category on the official KRX registry, effective July 1, 2024.
Investors must emphasize that this specific filing details only the pre- and post-modification classifications and the regulatory grounds for the update. Any implications regarding future pipeline schedules, capital expenditures, or operational changes are parameters that remain completely outside the scope of this regulatory disclosure. Investors should not interpret this administrative terminology alignment as an indicator of commercial or product portfolio shifts.
Consequently, the objective checkpoint for investors to monitor going forward is to verify that the sub-class industry description is updated to “Manufacture of basic pharmaceutical products” within the official KRX corporate database and future periodic corporate filings after the July 1, 2024 effective date. Tracking these registry listings remains the necessary pathway to verifying compliance with the updated classification guidelines.
📢 Disclaimer & Source Information
Source: This content has been structured and newly drafted based on official data submitted to the Financial Supervisory Service Electronic Disclosure System (DART).
Investment Risk Warning: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial liabilities rest solely with the investor.
Inquiries: For compliance inquiries or copyright-related requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
